California, Camelot and Vaccines

The New York Times

One of the New York Times most celebrated editorial writers writes a powerful critique of the fearmongering and misinformation used by advocates to attack the science of vaccines.

The New York Times

  • Topped our upper estimate! Evolva raises CHF 86M ($86M). Cash position now > CHF 100M ($100M).

Sign up to receive our
Press Releases!

Sign up